Free EHR, EHR and Healthcare IT Newsletter Want to receive the latest updates on EHR, EMR and Healthcare IT news sent straight to your email? Get all the latest EHR News for FREE!

ALLSCRIPTS TAKES $200M EQUITY POSITION IN NANTHEALTH AND EXPANDS STRATEGIC ALLIANCE TO ENHANCEPRECISION GENOMIC MEDICINE AT POINT OF CARE

New Agreement Calls For Accelerating Delivery and Coordination of 21st Century Evidence Based Precision Medicine

CHICAGO and CULVER CITY, CA – June 30, 2015 – Allscripts (Nasdaq: MDRX) (“Allscripts”), a global leader in healthcare information technology solutions, and NantHealth, a cloud-based information technology company, announced they have taken a significant step forward in their strategic partnership through two cross-investments and a strengthening of their commercial agreement. The investments include Allscripts’ purchase of a 10% equity stake in NantHealth for $200 million in cash. In addition, NantCapital, LLC, the personal investment vehicle of Dr. Patrick Soon-Shiong, founder of NantHealth, has made a $100 million investment into Allscripts.

NantHealth is a healthcare IT company providing the most comprehensive genomic and protein-based molecular diagnostics testing in the market today through its first in class Genomic Proteomic Sequencing (GPS Cancer) diagnostic test, applying this actionable health information to create personalized cancer treatment plans through its sophisticated care planning tool Eviti. NantHealth is in the process of bringing GPS Cancer to the point of care and into the patient’s home through a single integrated clinical platform. The Company’s vision is to allow IDNs, Academic Medical Centers, Pediatric Centers, physicians, patients, payers, employers, researchers and pharma to coordinate personalized cancer care, enable access to cutting edge clinical trials, monitor outcomes and control cost in real-time.

The investments and commercial agreement strengthen the partnership between Allscripts and NantHealth, originally announced in March 2015, to develop an integrated, evidence-based, personalized approach to healthcare solutions, and specifically cancer care. The companies will use Allscripts’ scale, global network of hospital and physician clients and leading software solutions, combined with NantHealth’s clinical platform, applications and connectivity devices to build out the infrastructure for new personalized, precision medicine programs for our clients to improve cancer care.

Going forward, NantHealth and Allscripts are focused on working together to accelerate the dissemination of technologies that seamlessly bring the promise of comprehensive molecular diagnostics to the routine, patient care setting. Specifically, the companies intend to work on joint development of: API-based integration between the two companies’ solutions; the creation of a cross clinical-GPS Cancer sequencing knowledge ontology and industry standard; the development of GPS Cancer sequencing invitations via the Allscripts FollowMyHealth® solution; integration of NantTransporter giving access to NantCancer Genome Browser, NantContraster and Paradigm and the development of an ACO solution incorporating semantic interoperability.

Research has shown that a physician’s ability to make effective, evidence-based clinical decisions can improve by using specifically matched cancer protocols and drugs, delivered to the patient based on the individual’s unique DNA, RNA and proteomic profile, and integrated with the patient’s holistic clinical picture. http://www.ascopost.com/issues/june-25,-2015/redefining-cancer.aspx For the first time, NantHealth and Allscripts can integrate these two aspects into a unique knowledge-based solution to significantly improve the way clinicians treat cancer.

Together, physicians and patients will have the tools to stay engaged and active and provide necessary intervention as early as possible. Leveraging innovations in patient engagement, care coordination and disease management; NantHealth and Allscripts are creating the first fully comprehensive and integrated platform that will provide a transformation to the coordination and delivery of personalized care across the spectrum of integrated health systems, across community ambulatory and tertiary practices.

Paul M. Black, President and Chief Executive Officer of Allscripts, said, “We’re taking an important step forward in our strategic partnership that fully aligns our resources and furthers Allscripts’ strategy to invest in new technologies that can revolutionize service to hospitals and physicians. Under the leadership of Dr. Soon-Shiong, NantHealth is pioneering extraordinarily innovative, personalized healthcare solutions that will empower more efficient and effective clinical decisions. We’re confident that our joint efforts will help Allscripts lead the way in our vision of delivering an open, integrated and precision-based medical solutions to physicians and patients.”

Dr. Soon-Shiong stated, “Since the NantHealth/Allscripts partnership began earlier this year, we have come to know Allscripts and its management team well, and I am confident that they can be a major contributor toward the execution of our vision. Allscripts has the technology and scale to become a significant player in a once-in-a-generation shift to personalized medicine. Pursuing unique and innovative partnerships such as this, which can integrate our solutions across the full spectrum of precision care, furthers our mission of building a healthcare ecosystem to drive better outcomes with the highest quality and lowest cost.”

Provider Reaction

“North Shore-LIJ has an established commitment to oncology research and the delivery of world-class cancer care,” said Michael J. Dowling, president and chief executive officer of the North Shore-LIJ Health System. “Today’s announcement of an expanded strategic alliance between NantHealth and Allscripts is exciting, both in terms of furthering our clinical mission and the opportunity to generate additional value from our long-term partnership with Allscripts. We look forward to participating in this alliance as we work together to deliver on the potential for truly personalized care.”

“Today’s healthcare providers are looking for innovative solutions that are integrated across the continuum of care,” said Robert L. Meyer, president and chief executive officer of Phoenix Children’s Hospital. “Allscripts and NantHealth offer a promising vision for how tomorrow’ssolutions will provide healthcare professionals with a personalized, comprehensive view of the patient, better analyze data, create precise protocols to drive down costs and improve patient outcomes throughout our healthcare system.”

Allscripts Adds New Sunrise Hospital Client

Allscripts also announced today that Windber Medical Center, a nonprofit, community healthcare provider, NantHealth client and affiliate, has selected the Allscripts Sunrise™ platform to be the new core electronic health record for its hospital facility, replacing its current electronic health system. Located in Somerset County, in Southwestern Pennsylvania, Windber Medical Center offers comprehensive primary and acute care including a critical care unit, home health and hospice care
fitness and wellness programs as well as the Joyce Murtha Breast Care Center.

“Windber Medical Center together with the CAP certified and Platinum rated human tissue repository at the Windber Research institute and its partnership with Walter Reed Medical Center is poised to be an integrated cancer center with the most cutting edge scientific genomic research in cancer, and our affiliation with NantHealth and Allscripts will propel us towards our mission of providing 21st century care at the community level,” said Tom Kurtz, CEO of Windber Medical Center.

NantCapital Investment in Allscripts

NantCapital’s investment has been executed through a private placement of Allscripts common stock. Allscripts received gross proceeds of approximately $100 million in the private placement. The combined impact of the expanded commercial agreement and cross-investments is expected to be modestly accretive to Allscripts earnings in 2016 and become increasingly accretive over the five-year term of the commercial agreement. The transaction does not change Allscripts 2015 guidance.

###

About Allscripts
Allscripts (Nasdaq:MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and It Takes A Community: The Allscripts Blog.

About NantHealth
NantHealth, a member of the NantWorks ecosystem of companies, is a healthcare transformational cloud-based IT company converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care, in the time of need, anywhere, anytime. NantHealth works to transform clinical delivery with actionable clinical intelligence at the moment of decision, enabling clinical discovery through real-time machine learning systems. The company’s technology empowers clinicians, patients and researchers to transcend the traditional barriers of today’s healthcare system. By converging molecular science, near real-time patient signal monitoring, computer science and big data technology, the NantHealth Clinical Operating System (cOS) platform empowers providers, patients, and commissioners to coordinate best care, monitor outcomes and control cost in real-time. This is the first system of its kind in healthcare, enabling 21st century coordinated care at a lower cost, enabling value-based population health management at a single patient level and at the population at large. For more information please visitwww.nanthealth.com and follow Dr. Soon-Shiong on Twitter @solvehealthcare.

About NantCancer Genome Browser
NantOmics, NantCancer Genome Browser enables clinicians for the first time to investigate a tumor genome from the full three billion bases down to the single-base level in real-time, thanks to the power of the NantOmics supercomputing and secure mobile infrastructure. The Cancer Genome Browser integrates with NantHealth’s treatment recommendation engine, Eviti, to personalize treatment protocols and clinical trail selection to individual patients based on their genomic and transcriptomic signature. The NantCancer Genome Browser is fully encrypted to allow deployment in a HIPAA secured environment, enabling clinicians to securely access patient data as soon as it’s available, wherever they
are.

About NantTransporter
Data transfer is one of the largest challenges associated with the analysis of sequencing data. NantOmics has designed an infrastructure capable of storing and processing thousands of genomes a day quickly and securely. Our NantTransporter software application enables secure transport of data directly from sequencing machines to NantOmics’s secure private genome processing cloud. Data streams are encrypted using 128-bit Advanced Encryption Standard (AES-128), the same algorithms designated for Top Secret government documents. Initiating a transfer is as easy as obtaining a transfer code from our web site, and specifying the files to be sent. Annotation of the genomes begins immediately with no downtime between transferring and the beginning of processing.

NantWorks has built a dark fiber network capable of Tb/sec transfers between hospitals, academic institutions and sequencing centers. In July 2012 we demonstrated the capabilities of NantTransporter by transferring 94 TB of genomic data and achieved speeds of up to 9.55 Gb/sec with a sustained rate of over 8.232 Gb/sec, the fastest and largest documented transfer of genomic data to date. To date we have transported over 15,000 cancer genomes via NantTransporter.

About NantContraster
Accurately assessing the state of a patient’s genome is one of the most powerful tools in the emerging field of personalized medicine. NantOmics applies its leading, novel genomic analyses to rapidly discover variants in a patient’s raw genomics data using the latest sequencing technologies combined with advanced statistics and machine learning techniques.

NantContraster annotates all variants against a knowledge database comprising all known and probable disease-associated genes to rank the genomic alterations that have the highest clinical relevance. When applied to cancer tumor/normal samples, our analysis is capable of quickly identifying genomic alterations that could lead to tumorigenesis for a fraction of the cost of conventional approaches. NantContraster is capable of concurrently processing many samples to handle large workflows from researchers and hospital settings.

About Paradigm
PARADIGM (Pathway Recognition Algorithm using Data Integration on Genomic Models) is a proprietary algorithm that uses a probabilistic graphical model to integrate multiple genomic data types on curated pathway databases and is unique for its per-sample approach that allows individual samples to be assessed alone or within the context of a cohort of interest.

June 30, 2015 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

Zoeticx Leverages Crowd Funding to Introduce TruRecord, Medical Prescribing Software That Will Address 2.2 Million Adverse Drug Reactions in U.S.

First EHR-integrated, Precise and Personalized, Mobile Platform to Leverage Advances in DNA Testing for Better Patient Outcomes and Lower Malpractice Payouts

June 29, 2015; San Jose, Calif — Zoeticx, Inc., the developer of medical software that bridges the gap between medical data and quality patient care, today announced a crowd funding campaign for TruRecord, the first subscriber-based, medical prescribing software to leverage advanced DNA testing technology for optimal drug analysis and prevention of adverse drug reactions.

The company is raising funds for a fall launch of TruRecord on medical crowd funding site Medstartr http://www.medstartr.com/projects/662-trurecord

TruRecord improves patient outcomes by reducing the 80,000 annual deaths due to drug adverse reactions, resulting in 289 billion spent annually on malpractice payouts. CDC ranks this as the fourth highest cause of deaths in US. With 30 new medications introduced yearly and 25 percent of patients on multiple medications, the need is growing.  The CDC also ranks this as the fourth highest cause of death in the U.S. after heart disease, cancer and strokes.

TruRecord is designed to foster better patient outcomes by helping to prevent the 100,000 deaths yearly from drugs that are prescribed properly and 80,000 deaths from those which are not, resulting in 289 billion spent annually on malpractice payouts.

Breaking Through Drug Analysis Limitations

Through an intuitive visualization of drug-to-drug interactions, drug-to-allergy interactions, and drug to DNA metabolization, medical professionals can now create what-if scenarios for drug issues, enabling providers to personalize prescriptions. This capability breaks through providers’ drug analysis limitations and the burdensome task of scanning and searching text and tables to identify adverse reaction data which is often complex.

These scenarios can now also be more complete with accurate patient medical information from any facility, including integration from existing hospital EHR’s through Zoeticx’s Patient-Clarity Platform which connects disparate EHR records and enables medical system interoperability.

Mobile Devices, HIPAA Compliance

TruRecord client interfaces are supported on mobile and web interfaces, providing precise, personalized medication prescriptions. TruRecord accesses patient medical records via an on-demand, real time access from EHR / EMR systems. Without data duplication, TruRecord complies with all required secure patient privacy protection outlined by HIPAA.

“We built Zoeticx to help medical systems address interoperability, lower accidental deaths and bridge the gap between medical data and better patient outcomes,” said Thanh Tran, CEO, Zoeticx. “Today our goal is the same, but a shift toward an additional focus—adverse drug reactions. We are ushering in an era where we can leverage the fruits of DNA research to bring more precise and accurate prescriptions to those who rely on them. TruRecord takes the guess work out of drug interactions and patients by delivering security, peace of mind and accuracy.”

About Zoeticx

Zoeticx offers software solutions for the healthcare industry which are dedicated to improving patient outcomes, enhancing the quality of care, containing costs, and simplifying administration. These solutions offer an immediate increase in the quality of care by delivering the right information to the right caregiver at the right time, in a manner that can be easily understood.  Additionally, as the Affordable Care Act continues to roll out, healthcare providers will face new challenges which arise whenever there is a transition from an old system of doing business to a new one. Zoeticx helps solve those challenges, allowing care providers to focus on what is most important, the patient. www.Zoeticx.com For additional information contact Glass Lantern PR at @glasslanternpr.com.

June 25, 2015 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

Dell and Translational Genomics Research Institute Help Support the Fight Against Pediatric Cancer Across Europe and the Middle East

DELL INNOVATION DAY, COPENHAGEN, Denmark, June 11, 2015 — Dell today announced its extended partnership with Translational Genomics Research Institute (TGen) to help clinical researchers and doctors globally expand the reach and impact of the world’s first Food and Drug Administration (John,FDA)-approved personalized medicine trial for pediatric cancer. The renewed commitment includes an additional $3 million Dell grant to support continued collaboration with TGen and support theNeuroblastoma and Medulloblastoma Translational Research Consortium’s (NMTRC) expanded  pediatric cancer clinical trials in EMEA, starting with sites in France and Lebanon. This is the second grant Dell has provided TGen to accelerate treatment of pediatric cancer, bringing its total contributions to more than $15 million since 2011.

The grant will also allow TGen to use Dell technology to bring genomic sequencing to point of diagnosis and enable TGen to extend its capabilities past pediatric cancer to support sequencing for other medical conditions affecting children including rare childhood diseases. By leveraging the capacity of Dell’s technology infrastructure, TGen is able to redirect some of its attention and resources to research rare disease sequences and help families get answers more quickly.

With most large hospitals lacking the time and budget to research pediatric cancer treatments, TGen’s aim is to reach and treat as many children as possible. However, when looking to support patients globally, it realized that it could no longer manage all of its data processing from the US. With time running out for many of its patients, TGen needed a solution that it could trust and that would reduce the amount of time needed to find and sequence genomic data. Based on a successful partnership in the US, TGen and Dell decided to extend its partnership and expand its support to EMEA.

“Time is of the essence in our line of work so we’re constantly undergoing vendor evaluations to try to find the right tool for the job. Dell understands what we’re trying to accomplish – not an easy claim in the world of quick-fire genome sequencing – and it has the partnerships and hardware to help us do it,” said James Lowey, Vice President of Technology, TGen.

TGen’s extended partnership with Dell will help it optimize a high-performance computing infrastructure to enable researchers to analyze and store massive amounts of genetic data more quickly and reach more patients than ever before. To date, TGen has been able to increase the number of computational hours by 376 percent and reduce the time it takes to analyze a patient’s molecular data – a process that used to take ten days – to six hours. These results will now be replicated in EMEA, as the infrastructure scales easily to handle the increased number of patients across the new sites.

“We are proud to help TGen in EMEA gain the speed and efficiency it needs to ensure that more children can benefit from timely, local and effective treatment.  Pediatric cancer is an issue that affects too many lives and we are committed to delivering benchmark solutions and support to ensure that the team at TGen are able to focus on this most important of work,” said Aongus Hegarty, President, Dell EMEA.

About Dell

Dell Inc. listens to customers and delivers innovative technology and services that give them the power to do more. As one of the leading providers of end-to-end IT solutions for healthcare worldwide, Dell helps healthcare organizations to simplify administration; coordinate and manage patient care; transition from episodic care to prevention and wellness management; and ultimately to deliver personalized medicine. As part of the company’s commitment to put technology and expertise to work where it can do the most good for people and the planet, Dell has been working with TGen since 2011 to accelerate pediatric cancer treatment. Learn more at http://www.dell.com/childrenscancercare or follow @DellHealth on Twitter.

About TGen

Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit).  TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org.

June 11, 2015 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

Medicare Limiting Coverage of Drug Sensitivity Testing as of June 22, 2015

New Ruling a Setback for Promise of Personalized Medicine

Seattle, WA (June 3, 2015) — On June 22, 2015, Medicare will begin denying coverage for the majority of genetic drug sensitivity (pharmacogenetic) testing that it has reimbursed since 2009.

Payment denial is expected to impact as many as 19 million of the 49 million Medicare beneficiaries in the U.S. who are at special risk of costly and life-threatening adverse drug events.1 Sadly, if it became a standard of care, this testing could save Medicare millions.

Precision Medicine, the use of an individual’s genetic information to tailor treatment, is by all accounts the future of healthcare. Despite the large body of clinical research supporting the utility of this testing – 17,000 pieces of clinical literature and counting – Medicare’s judgement that there is insufficient evidence to demonstrate that genetic testing improves clinical outcomes could set back adoption of this life-saving test by years.

What is Pharmacogenetic Testing?

Pharmacogenetic (PGx) testing reveals genetic variations that determine how the body metabolizes many of the most commonly prescribed medications. The testing reduces “trial-and-error” prescribing by enabling doctors to prescribe the most effective drug and dose the first time, potentially reducing side effects while saving both the patient and the healthcare system as a whole time and money.

Why is Pharmacogenetic Testing Important?

Research has shown that three out of four people have a genetic variation affecting their response to drugs. Genetically determined variation in drug response is so common that the FDA has included information about drug-gene interactions on more than 130 medication product inserts.

The potential cost-savings of widespread pharmacogenetic testing is huge.  According to the CDC, adverse drug events cost the U.S. health system approximately $3.5 billion annually.2 More than a third of potential clinically significant drug interactions, a potential cause of adverse drug events, have been shown to involve genetics.3  Recent analysis of the recently released CMS Medicare Part D prescription drug data from 2013 suggests:

  • $1.5 billion and 38,000 lives — that’s what genetic testing could potentially save for acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI), who are on the heart medications clopidogrel (Plavix), prasugrel, and ticragelor. In total, 2.9 million Medicare recipients were on at least one of these medications. Medicare spent $894 million on these drugs combined, with Plavix/clopidogrel costs representing 80 percent of that figure.4
  • Between 560,000 and 1.1 million Medicare recipients could be experiencing ineffective pain relief due to genetic variability while taking hydrocodone-acetaminophen, the prescription painkiller taken by the highest number of Medicare patients. In 2013, Medicare spent roughly $567 million on this drug for 8 million individual beneficiaries (about $70 per person). This is even more alarming considering untreated pain is a leading cause for falls, leading to hospitalization in the elderly.

Impact on the Elderly

Statistics show that adverse drug reactions, a specific subset of adverse drug events, cause 1 in 8 hospitalizations, with the elderly being twice as likely to be hospitalized by an adverse drug reaction compared to the non-elderly.5,6 Though it’s unclear how many of these are caused by drug-gene interactions, many Medicare patients are at particularly high risk, since 44 percent of men and 57 percent of women over 65 take five or more medications per week.7 Additionally, the metabolism of six of the top 10 drugs by Medicare claim count is potentially affected by genetics.

“Pharmacogenetic testing has been a covered benefit since 2009. Denying payment for these medically necessary tests is counter to the Triple Aim. Use of these tests could help doctors avoid unnecessary treatment failures and dangerous side effects; plus could reduce the more than $2000 per patient per year Medicare spends on adverse drug events,” said Kristine Ashcraft, Chief Operating Officer at Genelex. “This testing is the underpinning of precision medicine that President Obama recently called out as a national priority, and is required for better patient care.”

The potential for improvements in patient care and costs are not lost on physicians, whose use of PGx testing continues to be on the rise. A 2012 survey published in Clinical Pharmacology and Therapeutics reports that 12 percent of physicians have ordered PGx testing in the last six months, and 26 percent anticipate ordering a test in the next six months.8 A survey completed in 2014, published in the journal Pharmacogenomics and Personalized Medicine, found that 20 percent of surveyed physicians had ordered a PGx test in the last year.9

Drug sensitivity tests remain available after June 22 from Genelex and other laboratories. Medicare patients talking multiple medications, experiencing treatment failures or unwanted side effects are encouraged to request this testing before the cut-off date (the public is encouraged to visit this patient information site:  http://genelex.com/seniors).  See links below for further information about Medicare and pharmacogenetic testing.

#   #   #

About Genelex

Genelex is a pioneer in comprehensive medication management, pharmacogenetic testing and analysis. Its patented YouScript® Personalized Prescribing Software is the only commercially-available medication management system to assess the cumulative effect of a patient’s genetics and entire drug regimen.  YouScript is an Allscripts Developer Program Approved Application and is used by healthcare providers, clinical researchers and managed and accountable care organizations. Founded in 1987, Genelex is based in Seattle and was one of the first labs to provide pharmacogenetic testing and interpretation. For more information, please go to: www.genelex.com or www.youscript.com.

Sources 

  1. Based on current figures from the Kaiser Foundation in a recent study about the incidence of high-risk medications in patients 65 and over, and phenotype frequency data.
  1. http://www.cdc.gov/medicationsafety/basics.html
  1. Verbeurgt P, Mamiya T, Oesterheld J. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics. 2014;15(5):655-65. Epub 2014/05/07. doi: 10.2217/pgs.14.6. PubMed PMID: 24798722.
  2. Figures are based on an economic model created to show the possible positive impact of pharmacogenetic testing on ACS/PCI patients, using recently released CMS Medicare Part D prescription drug data that detailed how many Medicare patients were prescribed clopidogrel (also known as Plavix), prasugrel, and ticragelor in 2013.
  1. Jansen PA, Brouwers JR. Clinical pharmacology in old persons. Scientifica. 2012;2012:723678. PubMed PMID: 24278735
  1. Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharmacy world & science : PWS. 2002;24(2):46-54.
  1. Woodruff B. Preventing polypharmacy in older adults. American Nursing Today. 2010; 5(10). Available from: http://www.americannursetoday.com/preventing-polypharmacy-in-older-adults/
  1. Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91(3):450-8. PubMed PMID: 22278335.
  1. Johansen Taber KA, Dickinson BD. Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmgenomics Pers Med. 2014;7:145-62. PubMed PMID: 25045280.

June 3, 2015 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

Tute Genomics Biomarker Discovery Platform to Support Brigham Young University’s Alzheimer’s Disease Genetics Research

Provo, Utah (July 22, 2014)  — Tute Genomics today announced that its genome annotation and discovery platform will support Brigham Young University’s (BYU) efforts to advance Alzheimer’s disease genetics research. This collaboration involves analysis and interpretation of next-generation sequencing data from more than 1,000 exomes and genomes to identify new genetic variants associated with the disease.

“Collaboration is the key to discovering novel variants in genomics research, and Tute Genomics is honored to play a role in supporting this important work,” said Dr. Kai Wang, President of Tute Genomics, “This is an example of how our platform significantly enhances the ability for researchers to identify disease genes and variants from thousands of genomes.”

Dr. John “Keoni” Kauwe is leading a group of scientists from the BYU College of Life Sciences that is leveraging Tute Genomics in a large-scale effort to better understand the genetic basis of Alzheimer’s disease. The causes of this brain disease are still not fully understood and traditional treatments have so far proven unsuccessful. Dr. Kauwe’s group is looking to utilize Tute Genomics’ biomarker discovery platform to identify novel targets that may be used for therapeutic interventions.

“We have been extremely impressed with the Tute platform thus far, and we already have a number of research findings we are evaluating. We are excited to utilize Tute’s technology to support our novel approaches to finding genetic variants associated with Alzheimer’s disease using exome and whole genome sequence data,” said Dr. Kauwe.

The Alzheimer’s Genetic Analysis Group is a collaborative effort led by Dr. John Hardy at University College London. Other Principal Investigators in this group include Dr. Kauwe from BYU, Drs. Alison Goate and Carlos Cruchaga at the Washington University School of Medicine, and Dr. Andrew Singleton at the National Institutes of Health. Late last year this group discovered a novel genetic variant that doubles a person’s risk of developing the disease later in life. The study included families that had several members with Alzheimer’s. The scientists sequenced and compared genes of those individuals affected by the disease and those who were not. They were then able to identify variations in a gene that appeared in affected family members. [1]

Another of their recent studies has helped lift the veil on some of the mystery surrounding the causes of Alzheimer’s. The research team analyzed data from more than 25,000 people and reported that a rare genetic mutation in TREM2, a gene with function in the immune and inflammatory response, increases the risk of Alzheimer’s disease. [2]

“Dr. Kauwe and the Alzheimer’s Genetic Analysis Group are making exciting progress towards understanding the genetic underpinnings of Alzheimer’s disease. The first step towards effective treatments and an eventual cure is to fully understand the genetics and neurobiology of the disorder,” said Dr. Reid Robison, co-founder and CEO of Tute Genomics.

About Tute Genomics

Tute Genomics is a Utah-based company developing innovative cloud-based solutions to accelerate genetic discovery and enable precision medicine. Tute developed a clinical genome interpretation platform that assists researchers in identifying disease genes and biomarkers, and assists clinicians/labs in performing genetic diagnosis. Given sequencing data on a genome or a panel of genes, Tute can return over 125 annotations on variants and genes, perform family-based, case/control or tumor sample analyses to identify causal disease genes, and generate clinical reports for clinicians to focus on clinically relevant and actionable findings. Tute is built on the expertise that developed ANNOVAR, the most widely used genome annotation & interpretation technology with over 750 scientific citations. To learn more please visit www.tutegenomics.com.

[1] “Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease.” Nature. 2014 Jan 23;505(7484):550-4. doi: 10.1038/nature12825.

[2] “TREM2 variants in Alzheimer’s disease.” New England Journal of Medicine. 2013 Jan 10;368(2):117-27. doi: 10.1056/NEJMoa1211851.

July 22, 2014 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.